| Drug Type Bispecific T-cell Engager (BiTE) | 
| Synonyms- | 
| Action stimulants, inhibitors | 
| Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), KRAS G12D inhibitors(GTPase KRas G12D inhibitors), KRAS G12V inhibitors(GTPase KRas G12V inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Preclinical | United States  | 05 Nov 2024 | 






